BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference

CAMBRIDGE, Mass., and BEIJING, China, May 04, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. BGNE, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston. The presentation is scheduled for 9:20 AM ET on Tuesday, May 8, 2018.

A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Investor Contact  

Lucy Li, Ph.D. 

+1 781-801-1800  

ir@beigene.com  

Media Contact

Liza Heapes

+ 1 857-302-5663

media@beigene.com 

                                                        

i
ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!